Budhi Ida Bagus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Budhi Ida Bagus has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Metria Ida Bagus
Medical Faculty, Sebelas Maret University, Indonesia
11 shared publicationsWibisono
7 shared publicationsSetyawati Ida Ayu
Medical Faculty, Pendidikan Ganesha University, Indonesia
6 shared publicationsHanis Setyono
5 shared publicationsMastini Ida Ayu Kade
Clinical Pharmacy Department, Moewardi General Hospital, Indonesia
4 shared publicationsSuwardi
4 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
The adverse outcomes and progressive nature of early-onset colorectal cancer
- 27 August 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessThe adverse outcomes and progressive nature of early-onset colorectal cancer
- Open Access
- 26 August 2026
- Published by Medip Academy in International Surgery Journal
- Vol. 13 (9) , 1724-1728
Overlapping symptoms of pelvic metastasis and degenerative spine disease in colorectal cancer: a challenge in early diagnosis
Colorectal cancer (CRC) is the second leading cause of cancer mortality worldwide. 90% of CRC-related deaths are due to metastasis. One of the rarer CRC metastases is bone metastasis, especially pelvic metastasis, with minor symptoms that frequently overlap with other degenerative diseases. The 85-year-old woman with CRC experienced progressive lower back pain radiating to both legs. CT scan showed degenerative spine disease. Further bone scan revealed lytic lesions on the superior pubic ramus, prompting a rare diagnosis of pelvic metastasis in CRC. The clinical symptoms exhibited by a late-onset CRC patient, consisting of lower back pain radiating to both legs, accidentally concealed the rare presence of pelvic metastasis. In this case, the bone metastasis was successfully diagnosed following a routine bone survey, underscoring the importance of this procedure. Delayed diagnosis plummets the median survival from 20-30 months to just 2-3 months; clinicians must be aware of minor skeletal symptoms and utilize early advanced imaging to avoid catastrophic diagnostic delays and poor treatment outcomes. This rare case of pelvic metastasis in a CRC patient highlights the importance of not undermining minor skeletal symptoms in CRC patients and thoroughly exploring the possible cause of symptoms to avoid underdiagnosis or delays in diagnosing rare metastasis that could potentially alter outcomes for the worse.
- 26 August 2026
- Published by Medip Academy in International Surgery Journal
- Vol. 13 (9) , 1724-1728
Open AccessOverlapping symptoms of pelvic metastasis and degenerative spine disease in colorectal cancer: a challenge in early diagnosis
Colorectal cancer (CRC) is the second leading cause of cancer mortality worldwide. 90% of CRC-related deaths are due to metastasis. One of the rarer CRC metastases is bone metastasis, especially pelvic metastasis, with minor symptoms that frequently overlap with other degenerative diseases. The 85-year-old woman with CRC experienced progressive lower back pain radiating to both legs. CT scan showed degenerative spine disease. Further bone scan revealed lytic lesions on the superior pubic ramus, prompting a rare diagnosis of pelvic metastasis in CRC. The clinical symptoms exhibited by a late-onset CRC patient, consisting of lower back pain radiating to both legs, accidentally concealed the rare presence of pelvic metastasis. In this case, the bone metastasis was successfully diagnosed following a routine bone survey, underscoring the importance of this procedure. Delayed diagnosis plummets the median survival from 20-30 months to just 2-3 months; clinicians must be aware of minor skeletal symptoms and utilize early advanced imaging to avoid catastrophic diagnostic delays and poor treatment outcomes. This rare case of pelvic metastasis in a CRC patient highlights the importance of not undermining minor skeletal symptoms in CRC patients and thoroughly exploring the possible cause of symptoms to avoid underdiagnosis or delays in diagnosing rare metastasis that could potentially alter outcomes for the worse.
- Open Access
- 13 August 2026
- Published by MDPI AG in Preprints.org
Solitary Brain Metastasis from Early-Onset Colorectal Cancer, Transient Response to Emergency Radiotherapy: A Rare Case Report
Colorectal cancer (CRC) is one of the most common malignancies worldwide, and while metastasis commonly occurs in the liver and lungs, brain metastases from CRC are rare. Solitary brain metastasis in young adults is particularly uncommon. This case report a rare presentation of brain metastasis in a patient with a history of colorectal cancer. Emergency radiotherapy is often considered for symptomatic patients with intracranial hypertension or rapid neurological deterioration, but its benefits may be transient in aggressive tumor biology. We report the case of a 35-year-old male with a history of T3N2bM1a colorectal adenocarcinoma who presented with new-onset neurological symptoms, including headaches and right-sided hemiparesis. CT imaging revealed multiple brain lesions, including solid and hemorrhagic components with erosion of the left frontalis bone and brain edema, suggestive of metastatic disease. Given the rapid neurological decline, the patient was managed with a multidisciplinary approach, including corticosteroids to reduce cerebral edema, followed by whole-brain radiotherapy (WBRT) to address the metastatic lesions. Neurological symptoms improved within days, with partial resolution of hemiparesis. Surgical resection was deferred due to high perioperative risk and patient preference. The clinical improvement was short-lived. Follow-up imaging at 3 months demonstrated lesion progression with increased mass effect, accompanied by worsening neurological function after 4 months. This case highlights the rare occurrence of solitary brain metastasis from CRC in a young patient. It underscores the potential but transient benefit of emergency radiotherapy in rapidly deteriorating neurological states. Early recognition, individualized treatment planning remain essential in optimizing quality of life.
- 13 August 2026
- Published by MDPI AG in Preprints.org
Open AccessSolitary Brain Metastasis from Early-Onset Colorectal Cancer, Transient Response to Emergency Radiotherapy: A Rare Case Report
Colorectal cancer (CRC) is one of the most common malignancies worldwide, and while metastasis commonly occurs in the liver and lungs, brain metastases from CRC are rare. Solitary brain metastasis in young adults is particularly uncommon. This case report a rare presentation of brain metastasis in a patient with a history of colorectal cancer. Emergency radiotherapy is often considered for symptomatic patients with intracranial hypertension or rapid neurological deterioration, but its benefits may be transient in aggressive tumor biology. We report the case of a 35-year-old male with a history of T3N2bM1a colorectal adenocarcinoma who presented with new-onset neurological symptoms, including headaches and right-sided hemiparesis. CT imaging revealed multiple brain lesions, including solid and hemorrhagic components with erosion of the left frontalis bone and brain edema, suggestive of metastatic disease. Given the rapid neurological decline, the patient was managed with a multidisciplinary approach, including corticosteroids to reduce cerebral edema, followed by whole-brain radiotherapy (WBRT) to address the metastatic lesions. Neurological symptoms improved within days, with partial resolution of hemiparesis. Surgical resection was deferred due to high perioperative risk and patient preference. The clinical improvement was short-lived. Follow-up imaging at 3 months demonstrated lesion progression with increased mass effect, accompanied by worsening neurological function after 4 months. This case highlights the rare occurrence of solitary brain metastasis from CRC in a young patient. It underscores the potential but transient benefit of emergency radiotherapy in rapidly deteriorating neurological states. Early recognition, individualized treatment planning remain essential in optimizing quality of life.
- Open Access
- 1 August 2026
- Published by Comprehensive Publications in International Journal of Surgery Science
- Vol. 10 (8) , 20-22
A progressive disease of bone metastasis in colorectal cancer: Basic consideration
As a result of its relatively low occurrence and the fact that its initial symptoms are not very specific, bone metastasis in colorectal cancer typically indicates that the illness has progressed to an advanced stage at the time of diagnosis. In addition to bone pain, patients may also present with pathological fractures, spinal instability, or neurological impairment. All of these conditions have the potential to significantly affect a patient's functional status and quality of life. Skeletal metastases are frequently discovered at a late stage, after major structural damage has already been done. This results in a reduction in the number of therapeutic choices available and an increase in morbidity. It is therefore essential to detect bone metastases at an early stage in order to minimize occurrences connected to the skeleton and to maximize the results for patients. The incorporation of modern imaging modalities, such as magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT), has resulted in an improvement in the capability to detect osseous lesions at an earlier stage. Increased understanding of risk factors and clinical red flags may also make it easier to diagnose orthopedic conditions in a timely manner and to send patients to orthopedic experts in a timely manner.
- 1 August 2026
- Published by Comprehensive Publications in International Journal of Surgery Science
- Vol. 10 (8) , 20-22
Open AccessA progressive disease of bone metastasis in colorectal cancer: Basic consideration
As a result of its relatively low occurrence and the fact that its initial symptoms are not very specific, bone metastasis in colorectal cancer typically indicates that the illness has progressed to an advanced stage at the time of diagnosis. In addition to bone pain, patients may also present with pathological fractures, spinal instability, or neurological impairment. All of these conditions have the potential to significantly affect a patient's functional status and quality of life. Skeletal metastases are frequently discovered at a late stage, after major structural damage has already been done. This results in a reduction in the number of therapeutic choices available and an increase in morbidity. It is therefore essential to detect bone metastases at an early stage in order to minimize occurrences connected to the skeleton and to maximize the results for patients. The incorporation of modern imaging modalities, such as magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT), has resulted in an improvement in the capability to detect osseous lesions at an earlier stage. Increased understanding of risk factors and clinical red flags may also make it easier to diagnose orthopedic conditions in a timely manner and to send patients to orthopedic experts in a timely manner.
- Open Access
- 1 August 2026
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 17 (4) , 547-555
Human Epidermal Growth Factor Receptor 2 Negative, Low, and Overexpression in Breast Cancer Patients: Study on Recurrence-Free and Overall Survival
- 1 August 2026
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 17 (4) , 547-555
Open AccessHuman Epidermal Growth Factor Receptor 2 Negative, Low, and Overexpression in Breast Cancer Patients: Study on Recurrence-Free and Overall Survival
- Open Access
- 27 May 2026
- Published by Medip Academy in International Surgery Journal
- Vol. 13 (6) , 1092-1100
Challenging treatment of enterovesical fistula: a scoping review of pros and cons
Enterovesical fistula (EVF) is rare, morbid conditions primarily caused by diverticulitis. However, Crohn’s disease and pelvic malignancies present distinct operative challenges. Objectives were to evaluate current EVF management strategies, highlighting clinical benefits, limitations, and evidence gaps. We performed a PRISMA-ScR-guided scoping review of PubMed and Scopus (January 2000-February 2026), including English-language clinical studies. We analyzed data on etiology, surgical approach [open vs. minimally invasive surgery (MIS)], bladder management, and patient outcomes. Elective colorectal resection with primary anastomosis is the preferred approach for benign EVF, achieving high closure rates with acceptable morbidity. MIS is increasingly adopted in experienced centers, decreasing length of stay and wound complications. However, conversion to open surgery remains common in hostile pelves (e.g., dense phlegmon, prior surgery). Bladder management favors a selective, organ-preserving approach using intraoperative leak testing, often safely omitting formal cystotomy and routine postoperative cystography. Regarding specific etiologies: Crohn’s-related EVF may initially respond to biologics but typically requires definitive surgery; malignant EVF necessitates en bloc resection, with prognosis driven by oncologic stage and patient frailty. Current management converges on elective one-stage resection, selective bladder preservation, and judicious use of MIS. The persistent heterogeneity in perioperative care underscores the need for prospective, multicenter trials to standardize pathways and optimize outcomes.
- 27 May 2026
- Published by Medip Academy in International Surgery Journal
- Vol. 13 (6) , 1092-1100
Open AccessChallenging treatment of enterovesical fistula: a scoping review of pros and cons
Enterovesical fistula (EVF) is rare, morbid conditions primarily caused by diverticulitis. However, Crohn’s disease and pelvic malignancies present distinct operative challenges. Objectives were to evaluate current EVF management strategies, highlighting clinical benefits, limitations, and evidence gaps. We performed a PRISMA-ScR-guided scoping review of PubMed and Scopus (January 2000-February 2026), including English-language clinical studies. We analyzed data on etiology, surgical approach [open vs. minimally invasive surgery (MIS)], bladder management, and patient outcomes. Elective colorectal resection with primary anastomosis is the preferred approach for benign EVF, achieving high closure rates with acceptable morbidity. MIS is increasingly adopted in experienced centers, decreasing length of stay and wound complications. However, conversion to open surgery remains common in hostile pelves (e.g., dense phlegmon, prior surgery). Bladder management favors a selective, organ-preserving approach using intraoperative leak testing, often safely omitting formal cystotomy and routine postoperative cystography. Regarding specific etiologies: Crohn’s-related EVF may initially respond to biologics but typically requires definitive surgery; malignant EVF necessitates en bloc resection, with prognosis driven by oncologic stage and patient frailty. Current management converges on elective one-stage resection, selective bladder preservation, and judicious use of MIS. The persistent heterogeneity in perioperative care underscores the need for prospective, multicenter trials to standardize pathways and optimize outcomes.
- Open Access
- 2 May 2026
- Published by MDPI AG in Preprints.org
Multi-Organ Metastasis in Early-Onset Colorectal Cancer: Emerging Patterns, Biological Drivers, and Therapeutic Implications
Early-onset colorectal cancer (EOCRC), defined as colorectal cancer diagnosed before the age of 50 years, has become an emerging global health concern due to its steadily increasing incidence. Compared with late-onset colorectal cancer, EOCRC often presents with more advanced disease and exhibits distinct clinical and biological characteristics. Notably, younger patients are more likely to present with synchronous metastases and multi-organ dissemination at the time of diagnosis. This mini-review summarises current evidence regarding metastatic patterns and the biological mechanisms underlying multi-organ metastasis in EOCRC. The liver remains the most common metastatic site in EOCRC, primarily due to portal venous drainage from the colorectal region. However, studies suggest that EOCRC patients have a higher likelihood of additional metastatic involvement of the lungs, peritoneum, and distant lymph nodes, with occasional spread to the bone and brain. Several biological mechanisms may contribute to this aggressive metastatic behaviour. Distinct molecular alterations, including KRAS and BRAF mutations and microsatellite instability, have been reported in EOCRC and may influence tumour progression and metastatic potential. In addition, tumour microenvironmental changes such as epithelial–mesenchymal transition and angiogenesis play critical roles in facilitating tumour invasion, intravasation, and colonisation of distant organs. Hereditary predisposition, lifestyle-related risk factors, and gut microbiome alterations have also been implicated in EOCRC pathogenesis. A clearer understanding of the metastatic cascade and its molecular drivers in EOCRC is essential for improving early detection and developing targeted therapeutic strategies. Future research integrating molecular profiling and clinical outcomes may help optimize personalised treatment approaches and improve prognosis in this increasingly recognised patient population.
- 2 May 2026
- Published by MDPI AG in Preprints.org
Open AccessMulti-Organ Metastasis in Early-Onset Colorectal Cancer: Emerging Patterns, Biological Drivers, and Therapeutic Implications
Early-onset colorectal cancer (EOCRC), defined as colorectal cancer diagnosed before the age of 50 years, has become an emerging global health concern due to its steadily increasing incidence. Compared with late-onset colorectal cancer, EOCRC often presents with more advanced disease and exhibits distinct clinical and biological characteristics. Notably, younger patients are more likely to present with synchronous metastases and multi-organ dissemination at the time of diagnosis. This mini-review summarises current evidence regarding metastatic patterns and the biological mechanisms underlying multi-organ metastasis in EOCRC. The liver remains the most common metastatic site in EOCRC, primarily due to portal venous drainage from the colorectal region. However, studies suggest that EOCRC patients have a higher likelihood of additional metastatic involvement of the lungs, peritoneum, and distant lymph nodes, with occasional spread to the bone and brain. Several biological mechanisms may contribute to this aggressive metastatic behaviour. Distinct molecular alterations, including KRAS and BRAF mutations and microsatellite instability, have been reported in EOCRC and may influence tumour progression and metastatic potential. In addition, tumour microenvironmental changes such as epithelial–mesenchymal transition and angiogenesis play critical roles in facilitating tumour invasion, intravasation, and colonisation of distant organs. Hereditary predisposition, lifestyle-related risk factors, and gut microbiome alterations have also been implicated in EOCRC pathogenesis. A clearer understanding of the metastatic cascade and its molecular drivers in EOCRC is essential for improving early detection and developing targeted therapeutic strategies. Future research integrating molecular profiling and clinical outcomes may help optimize personalised treatment approaches and improve prognosis in this increasingly recognised patient population.
- Open Access
- 1 January 2026
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 17 (1) , 9-13
Delayed Presentation of Metachronous Ascending Colonic Adenocarcinoma in Early-Onset Colorectal Cancer Undergoing Curative Resection
Colorectal cancer (CRC) is the third most common cancer in both age groups in the world and one of the increasing causes of mortality each year. Particularly in early-onset colorectal cancer (EOCRC), this age group tends to metastasize to distant organs like the liver, lung, bone, and brain and in metachronous cases. Metachronous cancer in the colorectal adenocarcinoma is usually found in the first 2 - 3 years following curative treatment, with delayed recurrences being extremely rare. We report a rare case of a 42-year-old male with a history of ascending colon adenocarcinoma diagnosed at the age of 31. He underwent curative R0 resection with lymph node involvement, followed by 6 months of adjuvant FOLFOX chemotherapy. He remained disease-free for 11 years under routine surveillance. In 2025, he presented with symptoms of bloody diarrhea and altered bowel habits. Imaging and colonoscopic biopsy revealed a new adenocarcinoma in the distal rectum, representing a delayed metachronous. Clinical staging confirmed localized rectal cancer with limited metastasis (T3N2bM1a). Despite surgical resection being indicated, the patient declined surgery and opted for systemic chemotherapy. He tolerated treatment well, maintained functional status, and reported a good quality of life. Delayed metachronous recurrence can occur in EOCRC even after standard adjuvant therapy and prolonged remission. EOCRC also has a chance to be a delayed metachronous case. Closed follow-up should be performed, particularly in the case of those who refused the operative treatment.
- 1 January 2026
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 17 (1) , 9-13
Open AccessDelayed Presentation of Metachronous Ascending Colonic Adenocarcinoma in Early-Onset Colorectal Cancer Undergoing Curative Resection
Colorectal cancer (CRC) is the third most common cancer in both age groups in the world and one of the increasing causes of mortality each year. Particularly in early-onset colorectal cancer (EOCRC), this age group tends to metastasize to distant organs like the liver, lung, bone, and brain and in metachronous cases. Metachronous cancer in the colorectal adenocarcinoma is usually found in the first 2 - 3 years following curative treatment, with delayed recurrences being extremely rare. We report a rare case of a 42-year-old male with a history of ascending colon adenocarcinoma diagnosed at the age of 31. He underwent curative R0 resection with lymph node involvement, followed by 6 months of adjuvant FOLFOX chemotherapy. He remained disease-free for 11 years under routine surveillance. In 2025, he presented with symptoms of bloody diarrhea and altered bowel habits. Imaging and colonoscopic biopsy revealed a new adenocarcinoma in the distal rectum, representing a delayed metachronous. Clinical staging confirmed localized rectal cancer with limited metastasis (T3N2bM1a). Despite surgical resection being indicated, the patient declined surgery and opted for systemic chemotherapy. He tolerated treatment well, maintained functional status, and reported a good quality of life. Delayed metachronous recurrence can occur in EOCRC even after standard adjuvant therapy and prolonged remission. EOCRC also has a chance to be a delayed metachronous case. Closed follow-up should be performed, particularly in the case of those who refused the operative treatment.
- Open Access
- 1 October 2025
- Published by Comprehensive Publications in International Journal of Surgery Science
- Vol. 9 (4) , 107-109
A paradigm shift in the treatment of advanced-stage lung cancer
In spite of the fact that lung cancer is one of the most prevalent diseases, with an increasing incidence as well as the continued occurrence of morbidity and death, our clinical practice needs to take into account a wide range of factors when determining the most appropriate treatment option for patients. The advanced stage of lung cancer is the most prevalent type of lung cancer, and it has already spread to other parts of the body, including distant and regional locations. This is especially true in developing nations like Indonesia. In addition to the fact that surgery is a curative option for these cancers, the advanced stage has a limited reaction whenever we perform a surgical procedure; there are still many opportunities for the tumour to spread and metastasise. When it comes to these advanced instances, our current perspective is that chemotherapy and radiotherapy have already been announced for several years with unfavourable clinical outcomes, regardless of whether the follow-up is for a short period of time or for a longer period of time.
- 1 October 2025
- Published by Comprehensive Publications in International Journal of Surgery Science
- Vol. 9 (4) , 107-109
Open AccessA paradigm shift in the treatment of advanced-stage lung cancer
In spite of the fact that lung cancer is one of the most prevalent diseases, with an increasing incidence as well as the continued occurrence of morbidity and death, our clinical practice needs to take into account a wide range of factors when determining the most appropriate treatment option for patients. The advanced stage of lung cancer is the most prevalent type of lung cancer, and it has already spread to other parts of the body, including distant and regional locations. This is especially true in developing nations like Indonesia. In addition to the fact that surgery is a curative option for these cancers, the advanced stage has a limited reaction whenever we perform a surgical procedure; there are still many opportunities for the tumour to spread and metastasise. When it comes to these advanced instances, our current perspective is that chemotherapy and radiotherapy have already been announced for several years with unfavourable clinical outcomes, regardless of whether the follow-up is for a short period of time or for a longer period of time.
- 6 September 2025
- Published by Sciencedomain International in Journal of Cancer and Tumor International
- Vol. 15 (4) , 177-186
Lung Cancer: The Current and Multimodality Treatment
Even though lung cancer is one of the most prevalent diseases, with an increasing incidence as well as the continued occurrence of morbidity and death, our clinical practice needs to consider a wide range of factors when determining the most appropriate treatment option for patients. The advanced stage of lung cancer is the most prevalent type of lung cancer, and it has already spread to other parts of the body, including distant and regional locations. This is especially true in developing nations like Indonesia. In addition to the fact that surgery is a curative option for these cancers, the advanced stage has a limited reaction whenever we perform a surgical procedure; there are still many opportunities for the tumour to spread and metastasise. This review aims to explore the evolving treatment landscape of advanced-stage lung cancer, focusing on molecular targeted therapy approaches and overcoming resistance mechanisms. When it comes to these advanced instances, our current perspective is that chemotherapy and radiotherapy have already been announced for several years with unfavourable clinical outcomes, regardless of whether the follow-up is for a short period of time or for a longer period of time.A significant advancement in the field of lung cancer treatment methods has been achieved with the implementation of molecular targeted therapy approaches. The use of these strategies has the potential to substantially raise the rate of progression-free survival as well as the overall response rate of the first-line drugs that are administered to patients who have been diagnosed with lung cancer. Nonetheless, the persistent problem of the development of resistance to molecular targeted therapy is something that must be taken into consideration when treating patients with advanced lung cancer. In order to circumvent this issue, it is necessary to either find new pharmacological targets or to use drug delivery systems that combine multiple agents.
- 6 September 2025
- Published by Sciencedomain International in Journal of Cancer and Tumor International
- Vol. 15 (4) , 177-186
Lung Cancer: The Current and Multimodality Treatment
Even though lung cancer is one of the most prevalent diseases, with an increasing incidence as well as the continued occurrence of morbidity and death, our clinical practice needs to consider a wide range of factors when determining the most appropriate treatment option for patients. The advanced stage of lung cancer is the most prevalent type of lung cancer, and it has already spread to other parts of the body, including distant and regional locations. This is especially true in developing nations like Indonesia. In addition to the fact that surgery is a curative option for these cancers, the advanced stage has a limited reaction whenever we perform a surgical procedure; there are still many opportunities for the tumour to spread and metastasise. This review aims to explore the evolving treatment landscape of advanced-stage lung cancer, focusing on molecular targeted therapy approaches and overcoming resistance mechanisms. When it comes to these advanced instances, our current perspective is that chemotherapy and radiotherapy have already been announced for several years with unfavourable clinical outcomes, regardless of whether the follow-up is for a short period of time or for a longer period of time.A significant advancement in the field of lung cancer treatment methods has been achieved with the implementation of molecular targeted therapy approaches. The use of these strategies has the potential to substantially raise the rate of progression-free survival as well as the overall response rate of the first-line drugs that are administered to patients who have been diagnosed with lung cancer. Nonetheless, the persistent problem of the development of resistance to molecular targeted therapy is something that must be taken into consideration when treating patients with advanced lung cancer. In order to circumvent this issue, it is necessary to either find new pharmacological targets or to use drug delivery systems that combine multiple agents.